A Phase 1 interventional study of ABBV-1606 and Placebo in Healthy Volunteer, sponsored by AbbVie. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1606 moves through the body of healthy adult participants.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 358 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of ABBV-1606 or placebo group 1 on day 1.
Drug: ABBV-1606 · Drug: Placebo
Participants will receive a single oral dose of ABBV-1606 or placebo group 2 on day 1.
Drug: ABBV-1606 · Drug: Placebo
Participants will receive a single oral dose of ABBV-1606 or placebo group 3 on day 1.
Drug: ABBV-1606 · Drug: Placebo
Participants will receive a single oral dose of ABBV-1606 or placebo group 4 on day 1.
Drug: ABBV-1606 · Drug: Placebo
Participants will receive a single oral dose of ABBV-1606 or placebo group 5 on day 1.
Drug: ABBV-1606 · Drug: Placebo
Oral Solution
Oral Solution
Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
Time frame: Up to approximately 35 days
Maximum observed plasma concentration (Cmax) of ABBV-1606
Cmax of ABBV-1606
Time frame: Up to approximately 5 days
Time to maximum observed plasma concentration (Cmax) (Tmax) of ABBV-1606
Tmax of ABBV-1606
Time frame: Up to approximately 5 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1606
AUCt of ABBV-1606
Time frame: Up to approximately 5 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1606
AUCinf of ABBV-1606
Time frame: Up to approximately 5 days
Apparent terminal phase elimination constant (β) of ABBV-1606
β of ABBV-1606
Time frame: Up to approximately 5 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1606
t1/2 of ABBV-1606
Time frame: Up to approximately 5 days
Apparent clearance (CL/F) of ABBV-1606
CL/F of ABBV-1606
Time frame: Up to approximately 5 days
Apparent volume of distribution (Vz/F) of ABBV-1606
Vz/F of ABBV-1606
Time frame: Up to approximately 5 days
Dose Normalized Cmax of ABBV-1606
Dose Normalized Cmax of ABBV-1606 will be assessed.
Time frame: Up to approximately 5 days
Dose Normalized AUC of ABBV-1606
Dose Normalized AUC of ABBV-1606 will be assessed.
Time frame: Up to approximately 5 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.